[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609970":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":338,"collaborators":11,"id":340,"slug":11,"hasResults":341,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":11,"eligibilityCriteria":345,"healthyVolunteers":341,"sex":346,"minAge":347,"maxAge":11,"enrollmentInfo":348,"targetDuration":11,"studyType":351,"phases":352,"briefSummary":354,"conditions":355,"keywords":358,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":376},{"fullName":5,"class":6},"Nurix Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NX-5948","EXPERIMENTAL",null,[13],"Drug: NX-5948",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Oral dose administered once daily. NX-5948 will be given in continuous 28-day cycles.",[9],[20],"Bexobrutideg",[22],{"name":23,"affiliation":5,"role":24},"Nurix Study Director","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Additional Site Contact Information","CONTACT","415-417-3418","clinicaltrials@nurixtx.com",[32,45,55,65,74,84,93,103,113,123,133,142,152,161,171,181,191,201,211,220,225,235,245,254,263,272,282,291,300,309,320,329],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":11},"City of Hope","RECRUITING","Duarte","California","91010","United States",{"type":40,"coordinates":41},"Point",[42,43],-117.97729,34.13945,{"lat":43,"lon":42},{"facility":46,"status":34,"city":47,"state":48,"zip":49,"country":38,"cosmosGeoPoint":50,"geoPoint":54,"contacts":11},"Colorado Blood Institute","Denver","Colorado","80218",{"type":40,"coordinates":51},[52,53],-104.9847,39.73915,{"lat":53,"lon":52},{"facility":56,"status":34,"city":57,"state":58,"zip":59,"country":38,"cosmosGeoPoint":60,"geoPoint":64,"contacts":11},"University of Miami","Coral Gables","Florida","33146",{"type":40,"coordinates":61},[62,63],-80.26838,25.72149,{"lat":63,"lon":62},{"facility":66,"status":34,"city":67,"state":58,"zip":68,"country":38,"cosmosGeoPoint":69,"geoPoint":73,"contacts":11},"Florida Cancer Specialists","Sarasota","34232",{"type":40,"coordinates":70},[71,72],-82.53065,27.33643,{"lat":72,"lon":71},{"facility":75,"status":34,"city":76,"state":77,"zip":78,"country":38,"cosmosGeoPoint":79,"geoPoint":83,"contacts":11},"Fort Wayne Oncology and Hematology","Fort Wayne","Indiana","46804",{"type":40,"coordinates":80},[81,82],-85.12886,41.1306,{"lat":82,"lon":81},{"facility":85,"status":34,"city":86,"state":77,"zip":87,"country":38,"cosmosGeoPoint":88,"geoPoint":92,"contacts":11},"Hematology Oncology of Indiana","Indianapolis","46260",{"type":40,"coordinates":89},[90,91],-86.15804,39.76838,{"lat":91,"lon":90},{"facility":94,"status":34,"city":95,"state":96,"zip":97,"country":38,"cosmosGeoPoint":98,"geoPoint":102,"contacts":11},"University of Iowa","Iowa City","Iowa","52242",{"type":40,"coordinates":99},[100,101],-91.53017,41.66113,{"lat":101,"lon":100},{"facility":104,"status":34,"city":105,"state":106,"zip":107,"country":38,"cosmosGeoPoint":108,"geoPoint":112,"contacts":11},"Maryland Oncology Hematology","Silver Spring","Maryland","20904",{"type":40,"coordinates":109},[110,111],-77.02609,38.99067,{"lat":111,"lon":110},{"facility":114,"status":34,"city":115,"state":116,"zip":117,"country":38,"cosmosGeoPoint":118,"geoPoint":122,"contacts":11},"Karmanos Cancer Center","Detroit","Michigan","48201",{"type":40,"coordinates":119},[120,121],-83.04575,42.33143,{"lat":121,"lon":120},{"facility":124,"status":34,"city":125,"state":126,"zip":127,"country":38,"cosmosGeoPoint":128,"geoPoint":132,"contacts":11},"Duke University","Durham","North Carolina","27705",{"type":40,"coordinates":129},[130,131],-78.89862,35.99403,{"lat":131,"lon":130},{"facility":134,"status":34,"city":135,"state":126,"zip":136,"country":38,"cosmosGeoPoint":137,"geoPoint":141,"contacts":11},"Novant Health Cancer Institute","Winston-Salem","27103",{"type":40,"coordinates":138},[139,140],-80.24422,36.09986,{"lat":140,"lon":139},{"facility":143,"status":34,"city":144,"state":145,"zip":146,"country":38,"cosmosGeoPoint":147,"geoPoint":151,"contacts":11},"University of Cincinnati","Cincinnati","Ohio","45221",{"type":40,"coordinates":148},[149,150],-84.51439,39.12711,{"lat":150,"lon":149},{"facility":153,"status":34,"city":154,"state":145,"zip":155,"country":38,"cosmosGeoPoint":156,"geoPoint":160,"contacts":11},"Oncology Hematology Care","Fairfield","45014",{"type":40,"coordinates":157},[158,159],-84.5605,39.34589,{"lat":159,"lon":158},{"facility":162,"status":34,"city":163,"state":164,"zip":165,"country":38,"cosmosGeoPoint":166,"geoPoint":170,"contacts":11},"UPMC Hillman Cancer Center","Pittsburgh","Pennsylvania","15232",{"type":40,"coordinates":167},[168,169],-79.99589,40.44062,{"lat":169,"lon":168},{"facility":172,"status":34,"city":173,"state":174,"zip":175,"country":38,"cosmosGeoPoint":176,"geoPoint":180,"contacts":11},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":40,"coordinates":177},[178,179],-86.78444,36.16589,{"lat":179,"lon":178},{"facility":182,"status":34,"city":183,"state":184,"zip":185,"country":38,"cosmosGeoPoint":186,"geoPoint":190,"contacts":11},"Texas Oncology - Center South","Austin","Texas","78705",{"type":40,"coordinates":187},[188,189],-97.74306,30.26715,{"lat":189,"lon":188},{"facility":192,"status":34,"city":193,"state":194,"zip":195,"country":38,"cosmosGeoPoint":196,"geoPoint":200,"contacts":11},"University of Utah","Salt Lake City","Utah","84112",{"type":40,"coordinates":197},[198,199],-111.89105,40.76078,{"lat":199,"lon":198},{"facility":202,"status":34,"city":203,"state":204,"zip":205,"country":38,"cosmosGeoPoint":206,"geoPoint":210,"contacts":11},"Virginia Cancer Specialists, PC","Fairfax","Virginia","22031",{"type":40,"coordinates":207},[208,209],-77.30637,38.84622,{"lat":209,"lon":208},{"facility":212,"status":34,"city":213,"state":204,"zip":214,"country":38,"cosmosGeoPoint":215,"geoPoint":219,"contacts":11},"Oncology & Hematology Associates of Southwest VA","Norfolk","23502",{"type":40,"coordinates":216},[217,218],-76.28522,36.84681,{"lat":218,"lon":217},{"facility":221,"status":34,"city":213,"state":204,"zip":214,"country":38,"cosmosGeoPoint":222,"geoPoint":224,"contacts":11},"Virginia Oncology Associates",{"type":40,"coordinates":223},[217,218],{"lat":218,"lon":217},{"facility":226,"status":34,"city":227,"state":11,"zip":228,"country":229,"cosmosGeoPoint":230,"geoPoint":234,"contacts":11},"CHU de Nantes","Nantes","44000","France",{"type":40,"coordinates":231},[232,233],-1.55336,47.21725,{"lat":233,"lon":232},{"facility":236,"status":34,"city":237,"state":11,"zip":238,"country":239,"cosmosGeoPoint":240,"geoPoint":244,"contacts":11},"Azienda Ospedaliero-Universitaria di Alessandria SS. Antonio e Biagio e Cesare Arrigo","Alessandria","15121","Italy",{"type":40,"coordinates":241},[242,243],8.61007,44.90924,{"lat":243,"lon":242},{"facility":246,"status":34,"city":247,"state":11,"zip":248,"country":239,"cosmosGeoPoint":249,"geoPoint":253,"contacts":11},"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola","Bologna","40138",{"type":40,"coordinates":250},[251,252],11.33875,44.49381,{"lat":252,"lon":251},{"facility":255,"status":34,"city":256,"state":11,"zip":257,"country":239,"cosmosGeoPoint":258,"geoPoint":262,"contacts":11},"Ospedale San Raffaele S.r.l.","Milan","20132",{"type":40,"coordinates":259},[260,261],9.18951,45.46427,{"lat":261,"lon":260},{"facility":264,"status":34,"city":265,"state":11,"zip":266,"country":239,"cosmosGeoPoint":267,"geoPoint":271,"contacts":11},"AUSL della Romagna UO Ematologia","Ravenna","48121",{"type":40,"coordinates":268},[269,270],12.20121,44.41344,{"lat":270,"lon":269},{"facility":273,"status":34,"city":274,"state":11,"zip":275,"country":276,"cosmosGeoPoint":277,"geoPoint":281,"contacts":11},"Pratia Hematologia Sp. z o.o.","Katowice","40-519","Poland",{"type":40,"coordinates":278},[279,280],19.02173,50.2597,{"lat":280,"lon":279},{"facility":283,"status":34,"city":284,"state":11,"zip":285,"country":276,"cosmosGeoPoint":286,"geoPoint":290,"contacts":11},"Pratia S.A.","Krakow","30-225",{"type":40,"coordinates":287},[288,289],19.93658,50.06143,{"lat":289,"lon":288},{"facility":292,"status":34,"city":293,"state":11,"zip":294,"country":276,"cosmosGeoPoint":295,"geoPoint":299,"contacts":11},"Aidport Sp. z o.o.","Skorzewo","60-185",{"type":40,"coordinates":296},[297,298],17.97006,54.16909,{"lat":298,"lon":297},{"facility":301,"status":34,"city":302,"state":11,"zip":303,"country":276,"cosmosGeoPoint":304,"geoPoint":308,"contacts":11},"Pratia Warszawa \u002F Pratia MTZ","Warsaw","02-172",{"type":40,"coordinates":305},[306,307],21.01178,52.22977,{"lat":307,"lon":306},{"facility":310,"status":34,"city":311,"state":312,"zip":313,"country":314,"cosmosGeoPoint":315,"geoPoint":319,"contacts":11},"Oxford University Hospitals NHS Foundation Trust","Headington","Oxford","OX3 9D","United Kingdom",{"type":40,"coordinates":316},[317,318],-1.21974,51.75737,{"lat":318,"lon":317},{"facility":321,"status":34,"city":322,"state":11,"zip":323,"country":314,"cosmosGeoPoint":324,"geoPoint":328,"contacts":11},"The Royal Marsden NHS Foundation Trust","London","SW3 6JJ",{"type":40,"coordinates":325},[326,327],-0.12574,51.50853,{"lat":327,"lon":326},{"facility":330,"status":34,"city":331,"state":11,"zip":332,"country":314,"cosmosGeoPoint":333,"geoPoint":337,"contacts":11},"The Christie NHS Foundation Trust","Manchester","M20 4BX",{"type":40,"coordinates":334},[335,336],-2.23743,53.48095,{"lat":336,"lon":335},{"type":339,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100609970",false,"NCT07221500","A Study of NX-5948 in Adults With CLL\u002FSLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed\u002FRefractory (R\u002FR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* Confirmed relapsed\u002Frefractory CLL\u002FSLL that meets iwCLL criteria for diagnosis and systemic treatment\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Must have received a covalent BTK inhibitor (BTKi), a non-covalent BTKi, and a BCL-2 inhibitor either in separate lines of therapy or in combination; a line of therapy is considered 2 or more consecutive cycles of a systemic anti-CLL\u002FSLL regimen\n* Participants with SLL must have measurable disease by radiographic assessment\n* Adequate organ and bone marrow function\n* Must sign an informed consent form indicating that he or she understands the purpose of the procedures required for the study and is willing to participate\n\nExclusion Criteria:\n\n* Known or suspected prolymphocytic leukemia or Richter's transformation before entering study\n* Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) before planned start of study drug\n\n  * Antibody therapy must stop at least 4 weeks before the first dose of study drug\n  * No other systemic anticancer therapy is allowed at the same time as this study; exception: continuation of hormonal therapy for breast and prostate cancer is allowed, if they are not on the list of prohibited concomitant medications in this study\n* Palliative limited-field radiotherapy within 7 days of the first dose of study or broad field radiotherapy within 28 days of first dose of study drug\n* Use of systemic corticosteroids \\>20 mg\u002Fday prednisone or equivalent within the 7 days before start of study drug except for those used as premedication for radio diagnostic contrast\n* Use of systemic immunosuppressive drugs other than systemic corticosteroids within 60 days before the first dose of study drug\n* Previously treated with a BTK degrader\n* Previous chimeric antigen receptor (CAR) T-cell therapy or allogeneic or autologous hematopoietic cell transplant within the past 90 days prior to enrollment\n* Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage within 6 months of planned start of study drug\n\nNote: Other Inclusion\u002FExclusion criteria may apply as defined in the protocol.","ALL","18 Years",{"count":349,"type":350},100,"ESTIMATED","INTERVENTIONAL",[353],"PHASE2","This is a study for patients with relapsed\u002Frefractory (R\u002FR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL\u002FSLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.",[356,357],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)",[359,360,361,362,363,364,9,365,366,356,357],"BTK Degrader","BTK Inhibitor","BCL-2 Inhibitor","B-cell Malignancy","Lymphoma","Bruton's Tyrosine Kinase","Targeted Protein Degradation","Chimeric Targeting Molecule (CTM)","2026-06-30",{"date":369,"type":370},"2026-07-02","ACTUAL",{"date":372,"type":370},"2025-10-15",{"date":374,"type":350},"2030-10",{"name":5,"class":6},32]